Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

BACKGROUND: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes. Limited information is available regarding its effect on heterologous boosting. We aim to evaluate the immunog...

Descripción completa

Detalles Bibliográficos
Autores principales: Montero, Stephanie, Urrunaga-Pastor, Diego, Soto-Becerra, Percy, Cvetkovic-Vega, Aleksandar, Guillermo-Roman, Martina, Figueroa-Montes, Luis, Sagástegui, Arturo A., Alvizuri-Pastor, Sergio, Contreras-Macazana, Roxana M., Apolaya-Segura, Moisés, Díaz-Vélez, Cristian, Maguiña, Jorge L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162476/
https://www.ncbi.nlm.nih.gov/pubmed/37207103
http://dx.doi.org/10.1016/j.jvacx.2023.100311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162476/
https://www.ncbi.nlm.nih.gov/pubmed/37207103
http://dx.doi.org/10.1016/j.jvacx.2023.100311

Ejemplares similares